Automation of the Elispot Technique: Past, Present, and Future

Journal of Laboratory Automation

Volumn 9, Issue 1, 2004, Pages 10-15

  Janetzki, Sylvia ^a  

^a Zellnet Consulting Inc   (United States)

Author keywords

automation; cell preparation; Elispot antibodies; Elispot assay; Elispot plates; Elispot readers; vaccine trial monitoring

Indexed keywords

ANTIBODY; ANTIGEN; CYTOKINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; CLINICAL RESEARCH; DRUG MONITORING; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; LABORATORY DIAGNOSIS; ROBOTICS; SENSITIVITY ANALYSIS; STANDARDIZATION; VACCINATION;

EID: 0842301392     PISSN: 22110682     EISSN: 15402452     Source Type: Journal    
DOI: 10.1016/S1535-5535-03-00084-4     Document Type: Article

References (25)

1. Czerkinsky C. C. Nilsson L. A. Nygren H. Ouchterlony O. Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 1983, 65, 109–121.
2. Sedgwick J. D. Holt P. G. A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J. Immunol. Methods 1983, 57, 301–309.
3. Tarkowski A. Czerkinsy C. Nilsson L. A. Nygren H. Ouchterlony O. Solid-phase enzyme-linked immunospot (ELISPOT) assay for the enumeration of IgG rheumatoid factor-secreting cells. J. Immunol. Methods 1984, 72, 451–459.
4. Czerkinsky C. C. Tarkowski A. Nilsson L. A. Ouchterlony O. Nygren H. Gretzer C. Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J. Immunol. Methods 1984, 72, 489–496.
5. Czerkinsky C. Andersson G. Ekre H.-P. Nilsson L.-A. Klareskog L. Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 1988, 110, 29–36.
6. Link H. Olsson O. Sun J. Wang W.-Z. Andersson G. Ekre H.-P. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 1991, 87, 2191–2196.
7. Ollson T. Sun J. Hillert J. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur. J. Immunol. 1992, 22, 1083–1087.
8. Jacobson E. Masjedi K. Ahlborg N. Lundeberg L. Karlberg A. T. Scheynius A. Cytokine production in nickel-sensitized individuals analysed with enzyme-linked immunospot assay: Possible implication for diagnosis. Br. J. Dermatol. 2002, 147, 442–449.
9. Lewis J. J. Janetzki S. Schaed S. Evaluation of CD8+ T cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer 2000, 87, 391–398.
10. Lalvani A. Pathan A. A. Durkan H. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001, 357, 2017–2021.
11. Addo M. M. Yu X. G. Rathod A. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77, 2081–2092.
12. Ovsyannikova I. G. Dhiman N. Jacobson R. M. Vierkant R. A. Poland G. A. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin. Diag. Lab. Immunol. 2003, 10, 411–416.
13. Wang F. Bade E. Kuniyoshi C. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 1998, 5, 2756–2765.
14. Pass H. A. Schwarz S. L. Wunderlich J. R. Rosenberg S. A. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the Elispot assay. Cancer J. Sci. Am. 1998, 4, 316–324.
15. Janetzki S. Palla D. Rosenhauer V. Lochs H. Lewis J. J. Srivastava P. K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study. Int. J. Cancer 2000, 88, 232–238.
16. Cui Y. Chang L.-J. Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function. Biotechniques 1997, 22, 1146–1149.
17. Herr W. Linn B. Leister N. Wandel E. Meyer zum Bueschenfelde K.-H. Woelfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha in response to peptide antigens. J. Immunol. Methods 1997, 203, 141–152.
18. Vaquerano J. E. Peng M. Chang J. W. C. Zhou Y.-M. Leong S. P. L. Digital quantification of the enzyme-linked immunospot (ELISPOT). Biotechniques 1998, 25, 830–835.
19. Cox J. H. Ferrari G. Kalams S. A. Lopaczynski W. Oden N. D'Souza P. M. ; The ELISPOT Collaborative Group. Results of an Elispot proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. J. Immunol. Methods (in press).
20. Shaw R. D. Merchant A. A. Groene W. S. Cheng E. H. Persistence of intestinal antibody response to heterologous rotavirus infection in a murine model beyond 1 year. J. Clin. Microbiol. 1993, 31, 188–191.
21. Kreher C. R. Dittrich M. T. Guerkov R. Boehm B. O. Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine Elispot assays. J. Immunol. Methods 2003, 278, 79–93.
22. Cox J. H. DeSouza M. Ratto-Kim S. Ferrari G. Weinhold K. Birx D. L. Accomplishing cellular immune assays for evaluation of vaccine efficacy in developing countries. In Manual Clinical Laboratory Immunology, 6th ed.; ASM Publications: Washington DC, 2002; pp 301–315.
23. Smith J. G. Liu X. Kaufhold R. M. Clair J. Caulfield M. J. Development and validation of a gamma interferon ELISPOT assay for quantification of cellular immune responses to varizella-zoster virus. Clin. Diag. Lab. Immunol. 2001, 8, 871–879.
24. Gazagne A. Claret E. Wijdenes J. A fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J. Immunol. Methods 2003, 283, 91–98.
25. Currier J. R. Kuta E. G. Turk E. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial Elispot assays. J. Immunol. Methods 2002, 260, 157–172.